[go: up one dir, main page]

WO2001083031A3 - Composition topique pour le traitement du psoriasis et d'affections cutanees associees au psoriasis - Google Patents

Composition topique pour le traitement du psoriasis et d'affections cutanees associees au psoriasis Download PDF

Info

Publication number
WO2001083031A3
WO2001083031A3 PCT/US2001/014011 US0114011W WO0183031A3 WO 2001083031 A3 WO2001083031 A3 WO 2001083031A3 US 0114011 W US0114011 W US 0114011W WO 0183031 A3 WO0183031 A3 WO 0183031A3
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
treatment
glucosamine
formulations
related skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/014011
Other languages
English (en)
Other versions
WO2001083031A2 (fr
Inventor
Lorraine F Meisner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioderm Inc
Original Assignee
Bioderm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL152592A priority Critical patent/IL152592A/en
Priority to AU2001259311A priority patent/AU2001259311B2/en
Priority to MXPA02010799A priority patent/MXPA02010799A/es
Priority to DE60136348T priority patent/DE60136348D1/de
Priority to AU5931101A priority patent/AU5931101A/xx
Priority to EP01932815A priority patent/EP1278574B1/fr
Application filed by Bioderm Inc filed Critical Bioderm Inc
Priority to NZ522709A priority patent/NZ522709A/en
Publication of WO2001083031A2 publication Critical patent/WO2001083031A2/fr
Publication of WO2001083031A3 publication Critical patent/WO2001083031A3/fr
Priority to NO20025263A priority patent/NO331668B1/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des compositions et leurs procédés d'utilisation pour le traitement du psoriasis et d'affections cutanées associées au psoriasis. Lesdites compositions contiennent des formulations cutanées topiques de glucosamine dans une base émolliente telle qu'une crème hydratante. En plus de la glucosamine, lesdites formulations peuvent contenir des substances kératolytiques telles qu'un extrait de goudron de houille ou de l'acide salicylique. Ces formulations peuvent également contenir de la glucosamine et des extraits d'herbes antioxydants et anti-inflammatoires tels que l'oleuropéine et la berbérine dans une base émolliente.
PCT/US2001/014011 2000-05-01 2001-05-01 Composition topique pour le traitement du psoriasis et d'affections cutanees associees au psoriasis Ceased WO2001083031A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2001259311A AU2001259311B2 (en) 2000-05-01 2001-05-01 Topical composition for the treatment of psoriasis and related skin disorders
MXPA02010799A MXPA02010799A (es) 2000-05-01 2001-05-01 Composicion topica para el tratamiento de psoriasis y trastornos de la piel relacionados.
DE60136348T DE60136348D1 (de) 2000-05-01 2001-05-01 Topische zusammensetzung zur behandlung von psoriasis und verwandten hautkrankheiten
AU5931101A AU5931101A (en) 2000-05-01 2001-05-01 Topical composition for the treatment of psoriasis and related skin disorders
EP01932815A EP1278574B1 (fr) 2000-05-01 2001-05-01 Composition topique pour le traitement du psoriasis et des affections cutanées associées au psoriasis
IL152592A IL152592A (en) 2000-05-01 2001-05-01 Topical composition for the treatment of psoriasis and related skin disorders
NZ522709A NZ522709A (en) 2000-05-01 2001-05-01 Topical composition for the treatment of psoriasis and related skin disorders comprising glucosamine and herbal extracts of berberine and oleuropein
NO20025263A NO331668B1 (no) 2000-05-01 2002-11-01 Topisk hud preparat for behandling av psoriasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/562,400 US6440465B1 (en) 2000-05-01 2000-05-01 Topical composition for the treatment of psoriasis and related skin disorders
US09/562,400 2000-05-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/221,344 A-371-Of-International US6759971B2 (en) 2000-09-13 2001-09-06 Trainline controller electronics
US10/845,089 Division US6980127B2 (en) 2000-09-13 2004-05-14 Trainline controller electronics

Publications (2)

Publication Number Publication Date
WO2001083031A2 WO2001083031A2 (fr) 2001-11-08
WO2001083031A3 true WO2001083031A3 (fr) 2002-04-11

Family

ID=24246147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014011 Ceased WO2001083031A2 (fr) 2000-05-01 2001-05-01 Composition topique pour le traitement du psoriasis et d'affections cutanees associees au psoriasis

Country Status (11)

Country Link
US (2) US6440465B1 (fr)
EP (1) EP1278574B1 (fr)
AT (1) ATE412417T1 (fr)
AU (2) AU5931101A (fr)
CZ (1) CZ303216B6 (fr)
DE (1) DE60136348D1 (fr)
IL (1) IL152592A (fr)
MX (1) MXPA02010799A (fr)
NO (1) NO331668B1 (fr)
NZ (1) NZ522709A (fr)
WO (1) WO2001083031A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816402B2 (en) 1999-03-19 2010-10-19 Bioderm, Inc. Compositions and methods for the treatment of skin

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217914B1 (en) * 1999-03-19 2001-04-17 Bioderm, Inc. Ascorbic acid composition and method for treatment of aging or damaged skin
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
FR2808191B1 (fr) * 2000-04-28 2004-03-05 Oreal Extrait de vegetal de l'espece olea europaea comme inhibiteur de no-synthase et utilisations
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US7713569B2 (en) * 2000-09-01 2010-05-11 Creagri, Inc. Hydroxytyrosol-rich composition from olive vegetation water and method of use thereof
JP3820218B2 (ja) * 2000-09-01 2006-09-13 クレアグリ， インコーポレイテッド 植物水からヒドロキシチロソール富化組成物を得る方法
JP2005508856A (ja) * 2001-05-23 2005-04-07 ケイ． ハムディ、ハムディ 血管形成を阻害する方法
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7815944B2 (en) * 2001-06-20 2010-10-19 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
EP1482909B1 (fr) * 2002-02-13 2018-07-04 Creagri, Inc. Procede et composition pour le traitement d'une inflammation
DE10213019A1 (de) * 2002-03-22 2003-10-02 Cognis Deutschland Gmbh Verwendung von Extrakten des Olivenbaumes als Antischuppenmittel
BG65352B1 (bg) * 2002-05-16 2008-03-31 "Софарма" Ад Средство за лечение на псориазис
US7468355B2 (en) * 2002-05-22 2008-12-23 H2Rc Corporation Methods for inhibiting cancer and scar formation
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
CA2503196C (fr) * 2002-10-21 2011-08-02 Metaproteomics, Llc Compositions traitant ou inhibant des etats pathologiques associes a la reaction inflammatoire
US7429396B2 (en) * 2003-02-25 2008-09-30 Bio-Botanica, Inc. Antifungal composition, its fungicidal effect on pathogenic dermatophytes, and process for inhibiting growth of fungi
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
FR2853549B1 (fr) * 2003-04-11 2007-11-09 Agronomique Inst Nat Rech Composition nutritionnelle ou therapeutique contenant le compose oleuropeine ou l'un de ses derives
ES2323708T3 (es) * 2003-05-22 2009-07-23 Metaproteomics, Llc Composiciones farmaceuticas antiinflamatorias para reducir inflamacion y el tratamiento o la prevencion de toxicidad gastrica.
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
US8633246B2 (en) * 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
US20050042233A1 (en) * 2003-08-21 2005-02-24 Christopher Marrs Stabilized compositions containing an oxygen-labile active agent and a fungal extract
US20050042306A1 (en) * 2003-08-21 2005-02-24 Christopher Marrs Stabilized compositions containing an oxygen-labile active agent
US7205006B2 (en) * 2003-09-25 2007-04-17 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
US20050152996A1 (en) * 2003-12-01 2005-07-14 BUTLER Donald Extracts of Mimulus aurantiacus for treating psoriasis and repelling insects
US7914831B2 (en) 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
US20080300198A1 (en) * 2004-08-09 2008-12-04 Kathleen Matt Olive Compositions and Methods for Treating Inflammatory Conditions
PT1809383E (pt) * 2004-10-19 2008-11-06 Boots Co Plc Composições cosméticas
WO2006138056A1 (fr) * 2005-06-15 2006-12-28 Apollo Pharmaceutical, Inc. Composition pharmaceutique comprenant de l’extrait de mahonia aquifolium pour le traitement du psoriasis
US9789149B2 (en) 2005-07-19 2017-10-17 Creagri, Inc. Vegetation water composition for treatment of inflammatory skin conditions
EP1928248A4 (fr) * 2005-08-09 2009-09-16 Metaproteomics Llp Modulation des proteines kinases a l'aide de produits a base de houblon ou d'acacia
US8758838B2 (en) * 2005-08-31 2014-06-24 Johnson & Johnson Consumer Companies, Inc. Anti-inflammatory compositions and methods of use
US8697152B2 (en) * 2005-08-31 2014-04-15 Johnson & Johnson Consumer Companies, Inc. Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract
US20070116778A1 (en) * 2005-11-22 2007-05-24 Fierro Arthur A Antibacterial, antiviral, and antifungal nutritional supplement: a combination of natural or neutraceutical compounds shown to have antibacterial, antiviral, and antifungal properties, to help boost the immune system in humans, and to protect against certain biowarfare diseases
NZ568860A (en) * 2005-12-09 2012-09-28 Metaproteomics Llc Protein kinase modulation by hops and acacia products
AU2007223560A1 (en) * 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
US20080124404A1 (en) * 2006-06-19 2008-05-29 Jingwen Liu Hypolipidemic and/or hypocholesteremic compounds obtainable from the goldenseal plant
TW200819121A (en) * 2006-06-20 2008-05-01 Metaproteomics Llc Hexahydro-isoalpha acid based protein kinase modulation cancer treatment
US20080051466A1 (en) * 2006-06-20 2008-02-28 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment
WO2008006581A2 (fr) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Nouvelles compositions
US20080057138A1 (en) * 2006-09-06 2008-03-06 Telford Holdings Ltd. Restorative skin cream
WO2008048076A1 (fr) * 2006-10-20 2008-04-24 Amorepacific Corporation Composition pour le traitement de la dermatite atopique comprenant de la glucosamine et des dérivés de cette dernière et procédé de traitement de la dermatite atopique faisant intervenir de la glucosamine et des dérivés de cette dernière
JP5175481B2 (ja) * 2006-10-23 2013-04-03 エーザイフード・ケミカル株式会社 軟骨再生促進剤
KR100834444B1 (ko) 2007-01-15 2008-06-09 원광대학교산학협력단 물푸레나무로부터 분리된 올레우로페인 화합물을 포함하는톡소플라즈마증 예방 및 치료용 약학조성물
EP2136827A4 (fr) * 2007-03-19 2012-06-27 Metaproteomics Llc Procédé et compositions pour favoriser la bonne santé des os et des articulations
WO2008140842A1 (fr) 2007-05-11 2008-11-20 Metaproteomics, Llc Procédés et compositions pour détoxification de métaux lourds
US20110111087A1 (en) * 2007-08-29 2011-05-12 Roberto Crea Food and beverage supplement
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
WO2009076428A1 (fr) * 2007-12-10 2009-06-18 Metaproteomics, Llc Modulateurs à base de 1,3-cyclopentadione substituée des protéine kinases multi-ciblées pour le cancer, l'angiogenèse et les voies inflammatoires qui y sont associées
NZ588927A (en) * 2008-04-02 2013-02-22 Metaproteomics Llc Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
EP2405904B1 (fr) * 2009-03-13 2018-12-05 DBV Technologies Procédé de traitement de l'eczéma
ES2349976B1 (es) * 2009-05-14 2011-11-10 Sanidad Y Residencias 21 Sa Utilizacion de extractos de hojas de olivo en una composicion farmaceutica para inducir angiogenesis y vasculogenesis.
CA2766834C (fr) 2009-06-30 2017-04-25 Derman Biomedicine Co. Ltd. Compositions contenant de la berberine ou des analogues de celle-ci pour traiter l'acne rosacee ou des troubles cutanes associes a une rougeur faciale
CN101991599A (zh) * 2009-08-24 2011-03-30 谭国梁 可使病变组织及病原体溶解消除的药物
IT1395509B1 (it) * 2009-09-02 2012-09-28 Bionap Srl Composizione per il trattamento della patologia emorroidaria e delle patologie correlate
EP2542246A1 (fr) * 2010-03-03 2013-01-09 Neocutis SA Compositions et procédés de traitement de dermopathies et d'affections cutanées au moyen de composés séquestrants à peptide antimicrobien
US8545904B1 (en) 2012-06-05 2013-10-01 Liquid Innovators, LLC Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US20160263092A1 (en) 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
TW201538156A (zh) 2013-12-19 2015-10-16 Twi Biotechnology Inc 小蘗鹼配方及其用途
KR101567735B1 (ko) * 2014-12-09 2015-11-09 동국대학교 산학협력단 면역 조절제 및 글루코사민을 포함하는 건선 예방, 개선 또는 치료용 조성물
HK1249068A1 (zh) 2015-06-24 2018-10-26 安成生物科技股份有限公司 小檗碱制剂的治疗用途
US9867827B1 (en) 2015-08-27 2018-01-16 Florida A&M University Methods and formulations for topical treatment of psoriasis
WO2022015374A1 (fr) * 2020-07-17 2022-01-20 Bioderm Inc. Composition topique pour le traitement du psoriasis et de troubles cutanés apparentés

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473551A (en) * 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
EP0281812A1 (fr) * 1987-02-18 1988-09-14 Milor Scientific, Ltd. Composition pour le traitement de l'acné
FR2732215A1 (fr) * 1995-03-28 1996-10-04 Sederma Sa Nouvelles compositions cosmetiques depigmentantes
US5795573A (en) * 1998-01-08 1998-08-18 Paradise; Lou Homeopathic pharmaceutical compositions
WO1998042309A1 (fr) * 1997-03-25 1998-10-01 Crandall Wilson T Composition topique hydratante et technique afferente
WO1998042348A1 (fr) * 1997-03-25 1998-10-01 Wilson Trafton Crandall Composition hydratante topique et methode associee
WO2000000186A1 (fr) * 1998-06-30 2000-01-06 American Medical Research, Inc. Procede de traitement des troubles topiques
WO2001017495A1 (fr) * 1999-09-09 2001-03-15 The Boots Company Plc Composition cosmetique contre les radicaux libres

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3232836A (en) * 1959-08-24 1966-02-01 Pfizer & Co C Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine
US3122535A (en) * 1961-06-02 1964-02-25 Benckiser Gmbh Joh A 5-nitro furfurylidene-d-glucosamine, and process of making same
US4294852A (en) 1973-11-01 1981-10-13 Johnson & Johnson Skin treating compositions
US4102995A (en) * 1976-05-13 1978-07-25 Westwood Pharmaceuticals Inc. Tar gel formulation
US4722936A (en) 1983-05-05 1988-02-02 Joseph Jacob Deodorization vaginal products and catamenials
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
US4647453A (en) 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US4818521A (en) 1985-04-18 1989-04-04 Sunstar Kabushiki Kaisha Emulsion cosmetic stably containing vitamin C
US4772591A (en) 1985-09-25 1988-09-20 Peritain, Ltd. Method for accelerated wound healing
US4983382A (en) 1987-01-27 1991-01-08 Avon Products, Inc. Cosmetic preparation incorporating stabilized ascorbic acid
US4938969A (en) 1988-11-14 1990-07-03 Milor Scientific, Ltd. Method for the treatment of aging or photo-damaged skin
DE3843238C1 (fr) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5140043A (en) 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US5554647A (en) * 1989-10-12 1996-09-10 Perricone; Nicholas V. Method and compositions for treatment and/or prevention of skin damage and aging
FR2658509B1 (fr) * 1990-02-22 1992-06-12 Roussel Uclaf
US5308621A (en) * 1991-02-18 1994-05-03 Commonwealth Scientific And Industrial Research Organisation Ascorbic acid composition and transdermal administration method
JP2609564B2 (ja) * 1991-05-31 1997-05-14 政夫 斎藤 アレルギー性皮膚炎用クリーム及びその製造方法
NZ249379A (en) * 1992-02-07 1998-07-28 Albert M Kligman A cosmetic treatment of inflammatory dermatoses by administering to the affected skin a composition comprising a corticosteroid and a retinoid
US5391373A (en) * 1992-07-01 1995-02-21 Chanel, Inc. Skin cream composition
DE4221537A1 (de) 1992-07-01 1994-01-05 Schwabe Willmar Gmbh & Co Hamamelis-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung als Arzneimittel
NL9201438A (nl) * 1992-08-11 1994-03-01 Prospa Bv Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
US5310742A (en) * 1992-11-30 1994-05-10 Elias Alan N Uses for thioureylenes
US5516793A (en) * 1993-04-26 1996-05-14 Avon Products, Inc. Use of ascorbic acid to reduce irritation of topically applied active ingredients
DE4328871A1 (de) * 1993-08-27 1995-03-02 Beiersdorf Ag Mittel gegen empfindliche, hyperreaktive Hautzustände, atopische Dermatiden, Pruritus, Psoriasis Prurigo, Photodermatosen und Ichthyosis
CA2120967A1 (fr) * 1994-04-11 1995-10-12 Boubaker Boussetta Medicament pour le traitement du psoriasis et des affections dermiques
JP3294449B2 (ja) 1994-12-02 2002-06-24 花王株式会社 細胞接着抑制剤
US5639740A (en) * 1995-03-10 1997-06-17 Crandall; Wilson Trafton Topical moisturizing composition and method
GB9515214D0 (en) * 1995-07-25 1995-09-20 Univ Strathclyde Plant extracts
GB2307176A (en) * 1995-11-15 1997-05-21 Todd Selwyn Everest Anti-inflammatory clathrating agents for topical use
US6395772B1 (en) * 1996-02-14 2002-05-28 National Institute Of Immunology Method for blocking endothelial cell-leukocyte attachment by inhibiting expression of adhesion molecules on the vascular endothelium for therapeutic applications
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
FR2760637B1 (fr) * 1997-03-11 1999-05-28 Fabre Pierre Dermo Cosmetique Extrait de goudron de houille a teneur reduite en hydrocarbures aromatiques, procede d'obtention et preparations dermo-cosmetiques
US5902591A (en) * 1997-04-03 1999-05-11 La Prairie Sa Stable topical cosmetic/pharmaceutical emulsion compositions containing ascorbic acid
AU8020698A (en) * 1997-05-21 1998-12-11 New Key Foods N.V. Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
IT1298283B1 (it) * 1998-02-19 1999-12-20 B & T S R L Uso dell'estratto delle foglie di olea europea come antiradicalico
US6110966A (en) * 1998-02-20 2000-08-29 Medi-Cell Laboratories, Inc. Triple action complex
US7816402B2 (en) * 1999-03-19 2010-10-19 Bioderm, Inc. Compositions and methods for the treatment of skin
US6217914B1 (en) * 1999-03-19 2001-04-17 Bioderm, Inc. Ascorbic acid composition and method for treatment of aging or damaged skin
US6011067A (en) * 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
US20050003023A1 (en) * 2002-06-28 2005-01-06 Meisner Lorraine Faxon Topical composition for the treatment of psoriasis and related skin disorders
US6440465B1 (en) 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473551A (en) * 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
EP0281812A1 (fr) * 1987-02-18 1988-09-14 Milor Scientific, Ltd. Composition pour le traitement de l'acné
FR2732215A1 (fr) * 1995-03-28 1996-10-04 Sederma Sa Nouvelles compositions cosmetiques depigmentantes
WO1998042309A1 (fr) * 1997-03-25 1998-10-01 Crandall Wilson T Composition topique hydratante et technique afferente
WO1998042348A1 (fr) * 1997-03-25 1998-10-01 Wilson Trafton Crandall Composition hydratante topique et methode associee
US5795573A (en) * 1998-01-08 1998-08-18 Paradise; Lou Homeopathic pharmaceutical compositions
WO2000000186A1 (fr) * 1998-06-30 2000-01-06 American Medical Research, Inc. Procede de traitement des troubles topiques
WO2001017495A1 (fr) * 1999-09-09 2001-03-15 The Boots Company Plc Composition cosmetique contre les radicaux libres

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816402B2 (en) 1999-03-19 2010-10-19 Bioderm, Inc. Compositions and methods for the treatment of skin
US7834055B2 (en) 1999-03-19 2010-11-16 Bioderm, Inc. Compositions and methods for the treatment of skin

Also Published As

Publication number Publication date
IL152592A0 (en) 2003-05-29
MXPA02010799A (es) 2004-09-06
IL152592A (en) 2008-12-29
AU2001259311B2 (en) 2005-12-08
CZ303216B6 (cs) 2012-05-30
AU5931101A (en) 2001-11-12
EP1278574B1 (fr) 2008-10-29
US7670620B2 (en) 2010-03-02
NO331668B1 (no) 2012-02-20
CZ20023854A3 (cs) 2003-06-18
WO2001083031A2 (fr) 2001-11-08
NO20025263L (no) 2002-12-19
ATE412417T1 (de) 2008-11-15
US20020164386A1 (en) 2002-11-07
NZ522709A (en) 2005-07-29
DE60136348D1 (de) 2008-12-11
US6440465B1 (en) 2002-08-27
NO20025263D0 (no) 2002-11-01
EP1278574A2 (fr) 2003-01-29

Similar Documents

Publication Publication Date Title
WO2001083031A3 (fr) Composition topique pour le traitement du psoriasis et d'affections cutanees associees au psoriasis
CA2774026C (fr) Compositions comprenant un melange anti-inflammatoire
Park et al. An anti-inflammatory principle from cactus
US4942033A (en) Vegetable extract-based cosmetic or pharmaceutical composition which acts on capillary brittleness
DK2606874T3 (en) Novel cosmetic and / or pharmaceutical compositions and their use / novel cosmetic and / or pharmaceutical Compositions and uses thereof
US5871743A (en) Topical application of soy molasses
WO2004037184A3 (fr) Methodes de traitement de troubles cutanes
IE831611L (en) Topical anti-inflammatory compositions
ATE338533T1 (de) Hautcremezusammensetzung
BRPI0606328B8 (pt) uso de um glicosídeo fenilpropanóide proveniente de uma planta de ajuga reptans, uso de um homogenato de células inteiras de ajuga reptans, uso de um extrato purificado de ajuga reptans e uso de fenilpropanóides provenientes de uma planta ajuga reptans
Niknam et al. Phytochemistry and Phytotherapeutic Aspects of Elaeagnus angustifolia L.
Nand et al. In vitro and in vivo assessment of polyherbal topical gel formulation for the treatment of acne vulgaris
KR102282645B1 (ko) 천궁 및 황금 혼합 추출물 또는 이들의 분리화합물을 함유하는 여드름 및 비듬완화용 화장료 조성물
JP4033981B2 (ja) テストステロン ５α−リダクターゼ阻害剤
WO2002072035A3 (fr) Compositions anti-inflammatoires et procedes d'utilisation
TW201801738A (zh) 包括羊蹄甲屬(bauhinia)的組成物、其製造方法以及將其使用於皮膚抗老化及其他皮膚應用的方法
KR101035955B1 (ko) 정좌초 추출물을 유효성분으로 함유하는 아토피성 피부 개선용 화장료 조성물
Farboud et al. Avena sativa: an effective natural ingredient in herbal shampoos for the treatment of hair greasiness
SI1363588T1 (sl) Farmacevtski in kozmeticni sestavki za zascito koze pred poskodbami zaradi soncnih zarkov
KR102801362B1 (ko) 항균 효능을 갖는 천연 알칼리 농축 온천수, 한방성분 및 일라이트를 포함하는 피부질환 개선 화장품 조성물
KR20050118820A (ko) 아토피성 피부염의 예방 효과를 가지는 조성물
JPH11189540A (ja) テストステロン−５α−レダクターゼ阻害剤
JPH0920644A (ja) 化粧水
KR102166248B1 (ko) 조팝나무 추출물의 활성분획물을 유효성분으로 함유하는 탈모예방 및 개선용 조성물
KR101035956B1 (ko) 밀통화 추출물을 유효성분으로 함유하는 아토피성 피부 개선용 화장료 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/010799

Country of ref document: MX

Ref document number: 152592

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2001259311

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2002-3854

Country of ref document: CZ

Ref document number: 522709

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001932815

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001932815

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-3854

Country of ref document: CZ

NENP Non-entry into the national phase

Ref country code: JP

WWP Wipo information: published in national office

Ref document number: 522709

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 522709

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001259311

Country of ref document: AU